Evidence map›Paper›PMID 29177124›Full record

ArticleCurrent transplantation reports2017

Harnessing Apoptotic Cells for Transplantation Tolerance: Current Status and Future Perspectives.

Anil Dangi, Xunrong Luo

Abstract read
In one paragraph

Article in Current transplantation reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anil DangiCenter for Kidney Research and Therapeutics, Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Xunrong LuoCenter for Kidney Research and Therapeutics, Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Northwestern University · US

Funding

Precision Cell Isolation and Analysis CoreP01AI112522 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUO, XUNRONG · 2015 to 2019
$11.9M
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet GraftsU01AI102463 · NIAID · UNIVERSITY OF MINNESOTA · PI HERING, BERNHARD JOSEF, LUO, XUNRONG · 2012 to 2016
$4.4M
Protein-Releasing Microporous Scaffolds for Cell Replacement TherapyR01EB009910 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUO, XUNRONG, SHEA, LONNIE D · 2010 to 2018
$3.5M
Modeling concurrent cytomegalovirus infection and transplantation toleranceR01AI114824 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUO, XUNRONG · 2016 to 2020
$1.4M
NIAID NIH HHS P01 AI112522NIAID NIH HHS R01 AI114824NIAID NIH HHS U01 AI102463NIBIB NIH HHS R01 EB009910
6 · The paper itself

Abstract

purpose of reviewThe use of donor apoptotic cells is an emerging therapy for inducing transplantation tolerance. In this review, we will discuss current understanding of mechanisms of this approach, as well as crucial aspects necessary for successful translation of this approach to clinical transplantation. RECENT

findingsTransplantation tolerance by donor apoptotic cells is mediated by their homeostatic interaction with recipient phagocytes, and subsequent expansion of suppressor cell populations as well as inhibition of effector T cells via deletion and anergy. To ensure their tolerogenicity, it is critical to procure non-stressed donor cells, and to induce and arrest their apoptosis at the appropriate stage prior to their administration. Equally important is the monitoring of dynamics of recipient immunological status, and its influences on tolerance efficacy and longevity. Emerging concepts and technologies may significantly streamline tolerogen manufacture and delivery of this approach, and smooth its transition to clinical application. SUMMARY: Hijacking homeostatic clearance of donor apoptotic cells is a promising strategy for transplantation tolerance. Timing is now mature for concerted efforts for transitioning this strategy to clinical transplantation.

Indexed as

Apoptotic cellsnanoparticlessensitizationsuppressor cellstolerancetransplantation

Identifiers

PMID29177124
PMCPMC5697727
OpenAlexW2761770771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.